UK microbiome firm Microbiotica has completed a €60m (£50m) financing round intended to fund its two lead oral live biotherapeutics (LBP) developed to tackle Ulcerative Colitis (UC).
A new study that examined the microbiomes of people living around the world has found that gut bacteria continuously acquire new functionality—depending on host lifestyle and industrialization.
Microbiotica is to contribute its reference genome database and culture collection of gut bacteria in a landmark study looking at the microbiome’s role in patients undergoing treatment for various cancers.